SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Rachlin Evan Lockwood (Last) (First) (Middle) C/O IAMBIC THERAPEUTICS, INC. 5627 OBERLIN DRIVE, SUITE 120 (Street) SAN DIEGO CA 92121 (City) (State) (Zip)	Iambic Therapeutics, Inc. [IAM] Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 10/16/2026 4. If Amendment, Date of Original Filed (Month/Day/Year)	☑ Director ☐ 10% Owner ☐ Officer (give title below) ☐ Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) ☑ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/16/2026		C		1,458,736	A	(1)(2)	1,458,736	I	See footnote(3)
Common Stock	10/16/2026		C		410,762	A	(4)	1,869,498	I	See footnote(3)
Common Stock	10/16/2026		P		718,750	A	$16	2,588,248	I	See footnote(3)
Common Stock	10/16/2026		C		57,754	A	(1)	57,754	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Convertible Preferred Stock	(1)	10/16/2026		C			1,152,025	(1)	(1)	Common Stock	1,152,025	$0	0	I	See footnote(3)
Series B Convertible Preferred Stock	(1)	10/16/2026		C			57,754	(1)	(1)	Common Stock	57,754	$0	0	I	See footnote(5)
Series B-3 Convertible Preferred Stock	(2)	10/16/2026		C			306,711	(2)	(2)	Common Stock	306,711	$0	0	I	See footnote(3)
Convertible Promissory Notes	(4)	10/16/2026		C			410,762	10/16/2026	08/14/2028	Common Stock	410,762	$0	0	I	See footnote(3)

Explanation of Responses:

1. Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

2. Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

3. The shares are held of record by Ascenta Capital Fund I, L.P., or Ascenta Capital Fund I. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Fund I, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Fund I. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

4. The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).

5. The shares are held of record by Ascenta Capital Project Turing SPV, L.P., or Ascenta Capital Project Turing. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Project Turing, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Project Turing. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

/s/ Sunny Chang, by power of attorney — 10/19/2026

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.